MedTrace Logo

Aliskiren in Patients With Idiopathic Membranous Nephropathy

NCT01093781 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2013-03-13

No results posted yet for this study

Summary

The goal of this proposal is to conduct a pilot study to access the antiproteinuric effect of aliskiren in patients with idiopathic membranous nephropathy. Patients will be treated for 3 months with aliskiren aiming to achieve the maximum tolerated dose and blood pressure (\>100 but \<125 mmHg systolic BP \>75% of the readings).

Conditions

  • Idiopathic Membranous Nephropathy

Interventions

DRUG

Aliskiren

Aliskiren dose will begin with 150mg per day and later up-titrated to the maximum available dose of 300mg per day.

Sponsors & Collaborators

Principal Investigators

  • Fernando Fervenza, MD, PhD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01093781 on ClinicalTrials.gov